Back to List View Graph View

Kelch-like ECH-associated protein 1 (KEAP1)

KEAP1 (Kelch-like ECH-associated protein 1) is a cytoplasmic regulatory protein best known for controlling the stability of nuclear factor erythroid 2-related factor 2 (Nrf2), a central transcription factor in cellular antioxidant defense.

Where the papers sit

20 papers from the last 6 months study Kelch-like ECH-associated protein 1 (KEAP1) directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 2 human data · 16 preclinical · 2 unclassified

Themes 4 themes · 1 paradigm shift

  • KEAP1-NRF2 Therapeutics

    KEAP1-NRF2 research is moving from pathway description toward targeted control of oxidative stress, inflammation and ferroptosis. PPI inhibitors such as inhaled GSK3227634 and compound 4-95 are being developed alongside natural products and pathway-directed nanoparticles. Recurrent applications include COPD, neurodegeneration, wound healing, neuroblastoma and cancer. Most evidence remains preclinical, with tissue selectivity, toxicity and durable target engagement unresolved.

    11 papers · 55%

  • Natural Antioxidant Therapies

    Plant extracts, purified phytochemicals and selenium nanoparticles are being explored as antioxidant interventions for colitis, diabetes and radiation injury. Nrf2, NQO1 and related defenses recur as candidate mechanisms, but chemical profiling and computational prediction often precede biological validation. The work favors multi-component natural products over single-target drugs. Dose consistency, active constituents and translation beyond experimental models remain open questions.

    4 papers · 20%

  • NRF2 in Metabolic Liver Disease

    MASLD research is linking NRF2 activity to steatosis, oxidative stress and liver graft resilience. Selective NRF2-target induction may persist even as NFE2L2 transcription falls across disease stages. The work also points to dysregulated m6A and compensatory arginine methylation as molecular changes that may prime premalignant progression. Whether NRF2 modulation can prevent MASLD-associated cancer remains open.

    2 papers · 10%

  • Others — NRF2-Associated Disease Research

    NRF2-linked work here spans metastatic non-small-cell lung cancer, doxorubicin-related cardiac injury and spinal muscular atrophy. In lung cancer, co-occurring STK11, KEAP1 and KRAS mutations are evaluated against clinical outcomes and progression-free survival. Separate studies examine carvacrol cardioprotection and omaveloxolone-induced NRF2 targets in SMA fibroblasts. These applications share a pathway but show no common therapeutic direction.

    3 papers · 15%

PARADIGM SHIFT

KEAP1 disruption and NRF2 hyperactivation can create, rather than prevent, cancer-treatment vulnerability

The pancreatic ductal adenocarcinoma CAR T-cell study and the DMAMCL-treated neuroblastoma study both challenge the assumption that KEAP1 loss or NRF2 activation is uniformly cytoprotective. In pancreatic tumors, genetic KEAP1 ablation or clinically observed KEAP1/NFE2L2 mutations enhanced susceptibility to CAR T-cell killing, while in MYCN-amplified neuroblastoma, DMAMCL binding to KEAP1 increased nuclear NRF2 and HMOX1, thereby inducing ferroptosis. Together, these findings make KEAP1-NRF2 hyperactivation a context-dependent therapeutic liability that can be exploited to improve tumor killing, rather than treating it only as a stress-resistance mechanism 42826199Oct 42444025Jul.

Papers

The 20 papers from the last 6 months that study Kelch-like ECH-associated protein 1 (KEAP1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

KEAP1-NRF2 Therapeutics (11)
  1. Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
  2. Effect of Lactiplantibacillus plantarum SCS6 on pancreatic oxidative damage in mice with type 2 diabetes based on gut-pancreas axis. Antonie van Leeuwenhoek · 15 Sept 2026 PMID 42742757
  3. A Subcellular Keap1-Nrf2 Disruption Strategy for Atopic Dermatitis Therapy. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720490
  4. The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein-Protein Interaction for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720473
  5. Neuroprotective Effects of Cistanoside A against Cadmium-induced Neurotoxicity via Keap1/Nrf2/NF-kB Signaling: In Vivo and In Silico approaches. Molecular neurobiology · 1 Sept 2026 PMID 42678483
  6. Sesamin Promotes Diabetic Wound Healing by Inhibiting Ferroptosis via the SIRT1/Keap1/Nrf2 Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 31 Aug 2026 PMID 42671318
  7. Integrated In Silico Discovery of Thymoquinone Analogs Targeting the Keap1-Nrf2 Pathway for Amyotrophic Lateral Sclerosis Therapy. ChemistryOpen · 19 Aug 2026 PMID 42613775
  8. Cross-Kingdom miR5054 Delivery via Polygonum cuspidatum-Derived Nanoparticles Enhances Burn Wound Healing by Regulating Microvascular Environment. ACS nano · 18 Aug 2026 PMID 42611244
  9. DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes. Redox report : communications in free radical research · 14 Jul 2026 PMID 42444025
  10. XPO1 inhibition induces NCOR1-Dependent oxidative stress to suppress hepatocellular carcinoma. Cell chemical biology · 7 Jul 2026 PMID 42413506
  11. A Keap1-Nrf2 protein-protein interaction inhibitor 4-95 ameliorates cognitive dysfunction by suppressing neuronal ferroptosis. Bioorganic chemistry · 20 Jun 2026 PMID 42322910
Natural Antioxidant Therapies (4)
  1. Caulerpa peltata extract protects against Dextran sodium sulfate-induced acute ulcerative colitis via modulating Nrf2 pathway. Die Naturwissenschaften · 26 Aug 2026 PMID 42645156
  2. Radio-Protective Effects of Selenium Nanoparticles Synthesized Using Aqueous Extract of Rhodiola on Mice Irradiated by 60Co γ-Rays. ACS biomaterials science & engineering · 23 Jun 2026 PMID 42335449
  3. Chemical Profiling and Scaffold-Based Drug-Discovery Analysis of Bioactive Compounds from Ceratonia siliqua L. with Computational and Biological Validation. Journal of chemical information and modeling · 28 May 2026 PMID 42206975
  4. Antidiabetic and antioxidant potentials of the ethyl acetate fraction of Momordica charantia leaf methanolic extract: in vitro and in silico studies. Bioorganic chemistry · 20 May 2026 PMID 42160833
NRF2 in Metabolic Liver Disease (2)
  1. Selective NRF2 target induction despite falling NFE2L2 transcription across the MASLD spectrum: implications for marginal donor grafts and KEAP1-targeted therapy. Free radical biology & medicine · 20 Oct 2026 PMID 42901279
  2. Dysregulated m6A via compensatory arginine methylation primes premalignancy in metabolic dysfunction-associated steatotic liver disease. Science advances · 9 Sept 2026 PMID 42715338
Others — NRF2-Associated Disease Research (3)
  1. Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736
  2. Pharmacological Activation of NRF2 by Omaveloxolone Upregulates NRF2-Target Proteins in SMA Type I Human Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 16 Jun 2026 PMID 42301137
  3. Exosomal MALAT1 expression associated with the cardioprotective effects of carvacrol in acute doxorubicin-induced cardiac injury: Potential involvement of Nrf2/Keap1-related signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 8 Jun 2026 PMID 42259137

By study type

Human data, design not indexed (2)
  1. Integrated In Silico Discovery of Thymoquinone Analogs Targeting the Keap1-Nrf2 Pathway for Amyotrophic Lateral Sclerosis Therapy. ChemistryOpen · 19 Aug 2026 PMID 42613775
  2. Chemical Profiling and Scaffold-Based Drug-Discovery Analysis of Bioactive Compounds from Ceratonia siliqua L. with Computational and Biological Validation. Journal of chemical information and modeling · 28 May 2026 PMID 42206975
Preclinical: animal, cell and lab studies (16)
  1. Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
  2. Effect of Lactiplantibacillus plantarum SCS6 on pancreatic oxidative damage in mice with type 2 diabetes based on gut-pancreas axis. Antonie van Leeuwenhoek · 15 Sept 2026 PMID 42742757
  3. A Subcellular Keap1-Nrf2 Disruption Strategy for Atopic Dermatitis Therapy. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720490
  4. The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein-Protein Interaction for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720473
  5. Dysregulated m6A via compensatory arginine methylation primes premalignancy in metabolic dysfunction-associated steatotic liver disease. Science advances · 9 Sept 2026 PMID 42715338
  6. Neuroprotective Effects of Cistanoside A against Cadmium-induced Neurotoxicity via Keap1/Nrf2/NF-kB Signaling: In Vivo and In Silico approaches. Molecular neurobiology · 1 Sept 2026 PMID 42678483
  7. Sesamin Promotes Diabetic Wound Healing by Inhibiting Ferroptosis via the SIRT1/Keap1/Nrf2 Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 31 Aug 2026 PMID 42671318
  8. Caulerpa peltata extract protects against Dextran sodium sulfate-induced acute ulcerative colitis via modulating Nrf2 pathway. Die Naturwissenschaften · 26 Aug 2026 PMID 42645156
  9. Cross-Kingdom miR5054 Delivery via Polygonum cuspidatum-Derived Nanoparticles Enhances Burn Wound Healing by Regulating Microvascular Environment. ACS nano · 18 Aug 2026 PMID 42611244
  10. DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes. Redox report : communications in free radical research · 14 Jul 2026 PMID 42444025
  11. XPO1 inhibition induces NCOR1-Dependent oxidative stress to suppress hepatocellular carcinoma. Cell chemical biology · 7 Jul 2026 PMID 42413506
  12. Radio-Protective Effects of Selenium Nanoparticles Synthesized Using Aqueous Extract of Rhodiola on Mice Irradiated by 60Co γ-Rays. ACS biomaterials science & engineering · 23 Jun 2026 PMID 42335449
  13. A Keap1-Nrf2 protein-protein interaction inhibitor 4-95 ameliorates cognitive dysfunction by suppressing neuronal ferroptosis. Bioorganic chemistry · 20 Jun 2026 PMID 42322910
  14. Pharmacological Activation of NRF2 by Omaveloxolone Upregulates NRF2-Target Proteins in SMA Type I Human Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 16 Jun 2026 PMID 42301137
  15. Exosomal MALAT1 expression associated with the cardioprotective effects of carvacrol in acute doxorubicin-induced cardiac injury: Potential involvement of Nrf2/Keap1-related signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 8 Jun 2026 PMID 42259137
  16. Antidiabetic and antioxidant potentials of the ethyl acetate fraction of Momordica charantia leaf methanolic extract: in vitro and in silico studies. Bioorganic chemistry · 20 May 2026 PMID 42160833
Unclassified: not yet indexed with MeSH (2)
  1. Selective NRF2 target induction despite falling NFE2L2 transcription across the MASLD spectrum: implications for marginal donor grafts and KEAP1-targeted therapy. Free radical biology & medicine · 20 Oct 2026 PMID 42901279
  2. Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736